Back to mobile site

Oppenheimer Reiterates Outperform Rating on Ascentage Pharma Group (AAPG)

March 27, 2026 5:59 AM EDT Send to a Friend
Oppenheimer analyst Matthew Biegler reiterated an Outperform rating and $45.00 price target on Ascentage Pharma Group (NASDAQ: AAPG).The analyst commented ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login